STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
https://doi.org/10.15789/1563-0625-2017-2-197-202
Abstract
At present time, there is an obvious need for a new generation of vaccines as the most effective preventive approach, in order to stop spreading of tuberculosis infection. So far, the most popular strategy is aimed at heterological vaccination. The idea is to use BCG, or improved BCG, or attenuated M. tuberculosis for primary vaccination. For the further booster vaccination one may apply thw s.c. subunit or vector vaccines, containing protective mycobacterial proteins. The aim of our investigation was to evaluate protective effects of a new vaccine based on recombinant bacterial proteins Ag85, ТВ10 and FliC. We used a model with aerosol M. tuberculosis H37Rv infection, and compared lung and spleen CFU counts and life-span of vaccinated versus non-vaccinated С57BL/6 mice. As a result, we revealed three vaccine variants with comparable protective capacity against BCG using our experimental model. The most promising variant is suggested for testing in preclinical trials.
About the Authors
V. V. Yeremeev
Central Tuberculosis Research Institute, Moscow
Russian Federation
Russian Federation
I. V. Duhovlinov
Research Institute of Experimental Medicine, St. Petersburg
Russian Federation
Russian Federation
A. I. Orlov
Research Institute of Experimental Medicine, St. Petersburg
Russian Federation
Russian Federation
A. F. Malenko
Central Tuberculosis Research Institute, Moscow
Russian Federation
Russian Federation
E. A. Fedorova
Research Institute of Experimental Medicine, St. Petersburg
Russian Federation
Russian Federation
M. B. Balazovsky
Pharma VAM Private Company, St. Petersburg
Russian Federation
Russian Federation
V. Ya. Gergert
Central Tuberculosis Research Institute, Moscow
Russian Federation
Russian Federation
References
1. Diel R., Nienhaus A., Lampenius N., Rüsch-Gerdes S., Richter E. Cost of multi drug resistance tuberculosis in Gtermany. Respir. Med., 2014, Vol. 108, no. 11, pp. 1677-1687.
2. Haile M., Källenius G. Recent developments in tuberculosis vaccines. Curr. Opin. Infect. Dis., 200, Vol. 18, no. 3, pp. 211-215.
3. Källenius G., Pawlowski A., Brandtzaeg P., Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb), 2007, Vol. 87, no. 4, pp. 257-266.
4. Kaufmann S.H. Tuberculosis vaccines: Time to think about the next generation. Semin. Immunol., 2013, Vol. 25, no. 2, pp. 172-181.
5. Liu J., Tran V., Leung A.S., Alexander D.C., Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum. Vaccin., 2009, Vol. 5, pp. 70-78.
6. Orme I.M. The Achilles heel of BCG. Tuberculosis (Edinburgh), 2010, Vol. 90, no. 6, pp. 329-332.
7. Raviglione M.C., Uplekar M.W. WHO’s new Stop TB Strategy. Lancet, 2006, Vol. 367, pp. 952-955.
8. Sepulveda R.L., Heiba I.M., King A., Gonzalez B., Elston R.C., Sorensen R.U. Evaluation of tuberculin reactivity in BCG-immunized siblings. Am. J. Respir. Crit. Care Med., 1994, Vol. 149, pp. 620-624.
Review
For citations:
Yeremeev V.V., Duhovlinov I.V., Orlov A.I., Malenko A.F., Fedorova E.A., Balazovsky M.B., Gergert V.Ya. STUDIES ON PROTECTIVE EFFECTS OF A VACCINE, BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS. Medical Immunology (Russia). 2017;19(2):197-202. (In Russ.) https://doi.org/10.15789/1563-0625-2017-2-197-202
Views:
9263
Email this article 